Generic Name and Formulations:
Ticarcillin (as disodium) 3g, clavulanate (as potassium) 0.1g; IV inj; sodium content 4.75mEq/g of ticarcillin; potassium content 0.15mEq/g of Timentin.
Indications for TIMENTIN:
Susceptible bacterial septicemia (adults only), lower respiratory, bone and joint, skin and skin structure, urinary tract, gynecologic and intraabdominal infections.
By IV infusion over 30 minutes. >60kg: Systemic and UTI: 3.1g every 4–6 hours. Gynecologic: moderate: 200mg/kg/day of ticarcillin in divided doses every 6 hours; severe: 300mg/kg/day in divided doses every 4 hours. <60kg: 200–300mg/kg/day in divided doses every 4–6 hours. Renal impairment: reduce dose; see literature.
<3months: not recommended. Give by IV infusion over 30 minutes. ≥3months: (<60kg): mild-to-moderate infections: 200mg/kg per day of ticarcillin in equal divided doses every 6 hrs: severe infections: 300mg/kg per day of ticarcillin in equal divided doses every 4 hours. ≥3months (≥60kg): mild-to-moderate infections: 3.1g every 6 hrs; severe infections: 3.1g every 4 hours. Renal impairment: reduce dose; see literature.
Cephalosporin, imipenem or other allergy. Not for use in children for septicemia or H. influenzae type b infections. Heart disease. Sodium restricted diets. Monitor serum electrolytes (esp. potassium) and renal, hepatic, hematopoietic function during prolonged therapy. Discontinue if bleeding problems occur and treat. Pregnancy (Cat.B). Nursing mothers.
Probenecid increases ticarcillin levels. May cause false (+) Coomb's test.
Antipseudomonal penicillin + β-lactamase inhibitor.
Inj site reactions, rash, pruritus, drug fever, GI upset, blood dyscrasias, hemorrhage, hypokalemia, superinfection, anaphylaxis, CNS stimulation, elevated liver enzymes.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|